枸橼酸伊沙佐米Ixazomib Citrate 4mg

This product is a proteasome inhibitor indicated for use in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

For use in combination with lenalidomide and dexamethasone The recommended initial dose of ixazomib citrate is 4 mg, administered orally once weekly on Days 1, 8, and 15 of a 28-day treatment cycle. The recommended initial dose of lenalidomide is 25 mg, administered orally once daily on Days 1 to 21 of a 28-day treatment cycle. The recommended initial dose of dexamethasone is 40 mg, administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle.

Thrombocytopenia: Monitor platelet counts at least monthly during treatment and adjust the dose as needed. Peripheral Neuropathy: Monitor patients for signs and symptoms of peripheral neuropathy and adjust the dose as needed. Peripheral Edema: Monitor for fluid retention. Investigate underlying causes when appropriate and adjust the dose as needed. Cutaneous Reactions: Monitor patients for the occurrence of rash and adjust the dose as needed. Thrombotic Microangiopathy: Monitor for signs and symptoms. Discontinue this product if thrombotic microangiopathy is suspected. Hepatic Toxicity: Monitor liver enzymes during treatment. Embryo-Fetal Toxicity: This product can cause fetal harm. Advise patients of the potential risk to the fetus and recommend the use of effective non-hormonal contraceptive methods.

Thrombocytopenia, neutropenia, diarrhea, constipation, peripheral neuropathy, nausea, peripheral edema, rash, vomiting, and bronchitis.

3 capsules per box.

Store tightly closed and protected from moisture, below 30℃. Keep out of the reach of children.